MedTrace Logo

Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis

NCT01321567 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2157

Last updated 2023-07-24

No results posted yet for this study

Summary

To investigate the efficacy and safety of PARIET twice daily (b.i.d.) in patients with Proton Pump Inhibitor-resistant reflux esophagitis

Conditions

  • Refractory Reflux Esophagitis

Interventions

DRUG

rabeprazole sodium

Doses of 10 mg or 20 mg twice daily may be administered orally to reflux esophagitis patients for a further 8 weeks when proton pump inhibitor treatment is ineffective. However, a dose of 20 mg twice daily should only be administered to patients with severe mucosa injury.

Sponsors & Collaborators

  • Eisai Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yoshinori Furuhata · Drug Fostering and Evolution Coordination Department, Corporate Regulatory Compliance, Safety and Quality Assurance Headquarters, Eisai Co., Ltd.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-01
Primary Completion
2013-03-01
Completion
2013-08-01

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01321567 on ClinicalTrials.gov